Jun 30, 2016 -4.87 - 4.22 - 4.61 ... 3,200,200
Jun 29, 2016 -4.22 - 4.07 - 4.15 ...... 276,400
Jun 28, 2016 -4.67 - 4.05 - 4.10 ... 1,289,900
Jun 27, 2016 -4.20 - 3.81 - 3.95 ...... 280,400
Jun 24, 2016 -4.40 - 3.93 -4.08 .....1,005,000
Jun 23, 2016 -4.26 - 3.92 -4.21 ........378,800
Jun 22, 2016 -4.17 - 3.85 -3.96 ....... 804,300
Jun 21, 2016 -4.29 - 3.95 -3.99 ....... 829,600
Jun 20, 2016 -4.19 - 3.90 -4.00 ....... 583,000
Jun 17, 2016 -4.75 - 4.75 -4.00 .... 2,078,500
Jun 16, 2016 -4.64 - 3.67 -4.59 .... 2,668,300
Jun 15, 2016 -4.28 - 3.96 -4.03 ....... 460,000
Jun 14, 2016 -4.40 - 4.07 -4.26 ....... 490,200
Certainly the end result of your thoughts are a significant probability. Big pharma has the disadvantage regarding cost of clinical trials. Acquisitions are definitely on their radar.
Jun 9th, 2016
Vascular Biogenics Ltd stock had its “buy” rating reaffirmed by analysts at Roth Capital in a research report issued to clients and investors on Thursday. They currently have a $22.00 target price on the biopharmaceutical company’s stock. Roth Capital’s price objective indicates a potential upside of 330.53% from the company’s previous close.
We'll find out Friday.
I agree that getting past Friday is important. Then early August conference call will be the next important date. I expect the news to remain outstanding.
1- Either severing the vascular pathway that supplies the tumor’s blood flow or destroying the tumor itself can kill the tumor. But attacking BOTH with the same therapy is a huge advance.
2- The CAR-T technology only attacks the tumor and those stocks, such as JUNO, using that technology are selling in significant double digits.
Here's a more complete statement. Very impressive. A double attack on both the tumor itself and its blood nourishment.
" The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor."
1- From the VBLT press release: "This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor."
2- Basically, the above statement fragment " regardless of baseline tumor mutations, " indicates that the TUMOR CAN NOT DISGUISE ITSELF. The VB111 treatment will still engage it despite it mutating. It can not hide.
3- The other statement fragment, "the identity of the pro-angiogenic factors secreted by the tumor" is an ATTEMPT BY THE TUMOR TO ESTABLISH BLOOD FLOW TO NOURISH ITSELF, but will be found, engaged and destroyed by VB-111.
4- The statement 1) above is very powerful.
Therapy may be able to treat all solid tumors.
Oxigene's pancreatic cancer treatments granted orphan drug status in Europe
Published: Mar 25, 2016 10:33 a.m.
SOUTH SAN FRANCISCO, Calif., March 25, 2016 (GLOBE NEWSWIRE) -- OXiGENE, a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the European Commission has granted orphan drug designation to CA4P for the treatment of gastro-entero-pancreatic neuroendocrine tumors (NETs). The designation provides for ten years of marketing exclusivity in European Union (EU) member countries following product approval. Earlier this year OXiGENE announced that CA4P received orphan drug designation from the U.S. Food and Drug Administration for NETs, which provides for seven years of marketing exclusivity after approval.
“I am pleased that the EU has provided the orphan designation to CA4P for neuroendocrine tumors,” stated William D. Schwieterman, M.D., President and Chief Executive Officer of OXiGENE. “This designation represents another successful step as we execute on our strategy of bolstering the proprietary position of CA4P in the potential indications in which we are most interested. Separately, we continue to expect final data from our phase 2a clinical trial of CA4P in NETs to be available later in 2016.”
Orphan designation in the EU is granted to product candidates that are intended to treat life-threatening or chronically-debilitating conditions that affect no more than five patients per 10,000 of the EU population. Among other benefits, orphan designation provides for regulatory assistance and scientific advice from the European Medicines Agency during product development.
Combination of FDA granted FAST TRACK & prior losses(NOL) exceeding $4 makes OXGN an appealing investment
Net Operating Losses (NOL) can be used by an acquiring company.
Patients with platinum-resistant/refractory ovarian cancer have POOR PROGNOSIS and might also be classified as chemotherapy-resistant/refractory ovarian cancer. Single-agent therapies used to treat this subset of patients include paclitaxel, PLD and topotecan. The response rate is in the 10–15% range and overall survival is approximately 12 months. Research is focusing on improving chemotherapy, introducing targeted agents and overcoming platinum resistance.
Great analysis. Thanks.
Trial Met Primary Endpoint of Improved Progression Free Survival. In addition to the overall survival trend reported by the GOG, it is important to remember that this study met its primary endpoint of PFS. The PFS was 7.3 months for patients receiving combination therapy and 4.8 months for the Avastin monotherapy arm (prospective 1-sided p-value; p=0.049; [HR=0.69]). The difference was greater in the platinum-resistant
population, with a median PFS of 6.7 months in the combination arm and 3.4 months for Avastin monotherapy (p=0.01; [HR=0.57]).
Overall Survival Benefit would be Important Differentiator in Ovarian Cancer. Progression free survival (PFS) is the approvable endpoint for ovarian cancer trials and, as discussed below, OXiGENE’s CA4P is well positioned with regard to this endpoint. However, physicians would prefer to have agents or combination strategies to improve OS, especially considering the lack of survival improvements with recently approved drugs. The initial survival results from the Phase II GOG study with CA4P are encouraging, and it is
worth noting that the data are less than 60% mature. It will be interesting to see further OS data as they are made available.